Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Cytoreductive surgery with intraperitoneal chemotherapy is one of the most important treatments for patients with colorectal cancer and peritoneal metastasis. For the best survival rates, complete removal of all metastatic lesions is the most important part of treatment, and various surgical procedures are required for the complete cytoreduction. Therefore, the postoperative morbidity rates are higher than those of localized colon cancer surgeries and patients can experience a prolonged recovery period and deterioration of physical activities over a long period. The aim of this study is to investigate the change of quality of life after cytoreductive surgery and intraperitoneal chemotherapy for colorectal cancer.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Cytoreductive surgery and intraperitoneal chemotherapy | Procedure | Cytoreductive surgery and intraperitoneal chemotherapy for colorectal cancer or pseudomyxoma peritonei. Either early postoperative intraperitoneal chemotherapy (EPIC) or hyperthermic intraperitoneal chemotherapy (HIPEC) is used for intraperitoneal chemotherapy. |
| Measure | Description | Time Frame |
|---|---|---|
| Brief pain inventory (BPI) | Pain recovery after cytoreductive surgery and intraperitoneal chemotherapy | Changes from baseline pain scores at postoperative 12 months |
| Measure | Description | Time Frame |
|---|---|---|
| European Organisation for Research and Treatment of Cancer (EORTC) Quality of life questionnaire (QLQ)-C30 | Qualify of life questionnaire for cancer patients | preoperative, postoperative 3 months, postoperative 6 months, postoperative 12 months, postoperative 24 months |
| EORTC QLQ for colorectal cancer |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Patients eligible for cytoreductive surgery and intraperitoneal chemotherapy for colorectal cancer peritoneal metastasis or pseudomyxoma peritonei
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Soo Yeun Park, MD | Contact | +82-10-8575-9619 | psy-flower@daum.net |
| Name | Affiliation | Role |
|---|---|---|
| Soo Yeun Park, MD | Colorectal Cancer Center, Kyungpook National University Chilgok Hospital | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Kyungpook National University Chilgok Hospital | Daegu | 41404 | South Korea |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D065426 | Cytoreduction Surgical Procedures |
| ID | Term |
|---|---|
| D013514 | Surgical Procedures, Operative |
Not provided
Not provided
Not provided
Not provided
Not provided
Quality of life questionnaire for patients with colorectal cancer |
| preoperative, postoperative 3 months, postoperative 6 months, postoperative 12 months, postoperative 24 months |
| Short-form(SF)-36 | Global measure of health-related quality of life | preoperative, postoperative 3 months, postoperative 6 months, postoperative 12 months, postoperative 24 months |
| Postoperative morbidity | Incidence and degree of surgical and medical complications after surgery | 90 days after surgery |
| Postoperative mortality | Incidence of postoperative mortality | 90 days after surgery |
| Postoperative recovery | Duration of hospital stay after surgery | 150 days after surgery |
| Brief pain inventory (BPI) | Pain recovery after cytoreductive surgery and intraperitoneal chemotherapy | preoperative, postoperative 3 months, postoperative 6 months, postoperative 24 months |